Cipla slips despite FDA nod for generic Ventolin; Morgan Stanley stays cautious
Summary
Cipla shares fall despite FDA approval for generic Ventolin; Morgan Stanley remains cautious amid significant stock underperformance.
Description
Cipla shares fall despite FDA approval for generic Ventolin; Morgan Stanley remains cautious amid significant stock underperformance.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source